Switzerland Innovation Park Basel Area opens site on Novartis Campus
Switzerland Innovation Park Basel Area has opened a new location at the Novartis Campus. From here, the innovation park’s operator, Basel Area Business & Innovation, is to support startups and companies from the fields of digital health and personalized medicine.
Startup atmosphere in the Switzerland Innovation Park Basel Area on the Novartis Campus (img: Adriano A. Biondo)
Over the coming years, Novartis is to increasingly open up its campus based in Basel to companies active in the area of life sciences. Basel Area Business & Innovation is the first major external organization to benefit from this approach. In this context, a press release explains how the investment and innovation promotion agency is able to open a new location for Switzerland Innovation Park Basel Area, which it operates, at the Novartis Campus.
From here, Basel Area Business & Innovation will now support startups and established firms from the fields of digital health and personalized medicine across an area of 580 square meters. “The objective is to establish a closeness between startups and the scientists from Novartis and thereby foster new forms of exchange, collaboration and innovation”, the press release states. A total of eight startups have already set up shop at the Novartis Campus, while the DayOne Accelerator is also based there. “For us, the proximity to Novartis is of huge interest because we provide software in the field of neurology that can be used both in everyday clinical practice and also in the testing of new medicines”, comments Sebastian Mathias Keller in the press release, Co-Founder and CEO of Rekonas Medical, which has moved into the new office space.
The Switzerland Innovation Park Basel Area therefore now has a fourth site. Previously, it was represented in Allschwil in the canton of Basel-Landschaft, Basel and Jura. “The opening of the site on the Novartis Campus is a godsend for us,” comments Christof Klöpper, CEO of Basel Area Business & Innovation, before adding: “We see it as a vote of confidence from Novartis and as recognition of the quality of the Switzerland Innovation Park Basel Area”.
Share this article
You may also be interested in
The biopharmaceutical company Kinarus has signed a capital commitment of up to 57 million Swiss francs with the investment group...Read More